ArticleAnnals of surgical oncology2025
Clinicopathologic Characteristics and Clinical Outcomes of Patients with Testicular Mesothelioma.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundMesothelioma of the tunica vaginalis testes (testicular mesothelioma [TM]) is a rare tumor, comprising less than 5% of mesotheliomas. Surgical intervention is the current standard of care, whereas the role of systemic therapies remains undefined.
methodsWe retrospectively reviewed 36 patients with pathologically confirmed TM treated at Memorial Sloan Kettering Cancer Center (MSK) between January 1996 to May 2023. Clinicopathologic data, treatments received, and clinical outcomes were reported. Surgical pathology samples, when available, underwent next-generation sequencing (NGS) using MSK-IMPACT. Overall survival (OS) was calculated by using the Kaplan-Meier method.
resultsMedian age at diagnosis was 64 years (range 24-93). Histologically, 22 (61%) tumors were epithelioid, ten (28%) were biphasic, three (8%) were sarcomatoid, and one (3%) was unable to be further classified. Ten patients (28%) had metastatic disease at initial diagnosis, and 13 more (36%) eventually developed metastatic disease. Orchiectomy was performed in 34 (94%) patients and retroperitoneal lymph node dissection (RPLND) in 12 (33%); 15 (42%) received systemic therapy and five (14%) radiation therapy. Ten samples underwent somatic NGS: five (50%) had CDKN2A/B, four (40%) had NF2, and two (20%) had BAP1 alterations. At a median follow up of 3.5 years, median OS was 4.5 years.
conclusionsThis is the largest single-institution series and genomic dataset for TM. We report unique clinicopathologic and genomic features that distinguish TM from other mesotheliomas, including a lower frequency of BAP1 alterations. Owing to the rarity of this disease, further refinement of the sequence and necessity of surgical and systemic treatment is necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.